BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?

No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!



BAILII [Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback]

United Kingdom Intellectual Property Office Decisions


You are here: BAILII >> Databases >> United Kingdom Intellectual Property Office Decisions >> Vetrapharm Limited and Alpharma; Vericore (Patent) [2002] UKIntelP o12502 (18 March 2002)
URL: http://www.bailii.org/uk/cases/UKIntelP/2002/o12502.html
Cite as: [2002] UKIntelP o12502

[New search] [Printable PDF version] [Help]


Vetrapharm Limited and Alpharma; Vericore [2002] UKIntelP o12502 (18 March 2002)

For the whole decision click here: o12502

Patent decision

BL number
O/125/02
Concerning rights in
GB 2270261 B
Hearing Officer
Mr S N Dennehey
Decision date
18 March 2002
Person(s) or Company(s) involved
Vetrapharm Limited and Alpharma; Vericore
Provisions discussed
PA.1977 1(1)(a), 1(1)(b) and 72
Keywords
Novelty, Revocation
Related Decisions
None

Summary

Vetrapharm Ltd and Alpharma sought revocation of the patent which concerned a second medical use of a pyrethroid for the treatment of sea lice infestation in sea water fish, such as salmon, on the grounds of lack of novelty and inventive step.

On a matter of construction it was decided that the term pyrethroid encompassed both pyrethrum which is a natural substance and synthetic pyrethroids based on expert evidence and extrinsic documents. Consequently earlier experiments using pyrethrum to delouse salmon destroyed the novelty of the invention. The disclosure of these experiments was considered enabling even though they may not have been sufficiently effective for commercial application.

The invention was also found to lack an inventive step, even on the basis of a narrow meaning of pyrethroid, it being obvious to delouse salmon using pyrethroids in light of the earlier experiments involving pyrethrum. The skilled person would have thought of using a synthetic pyrethroid instead of pyrethrum because there was a reasonable expectation that routine experimentation would establish a therapeutic dose (ie. one toxic to lice but not fish) for synthetic a pyrethroid as it had for pyrethrum. The patent was therefore revoked in its entirety.



BAILII: Copyright Policy | Disclaimers | Privacy Policy | Feedback | Donate to BAILII
URL: http://www.bailii.org/uk/cases/UKIntelP/2002/o12502.html